John Mendlein, Director at Fate Therapeutics, holds 311.23K shares in Fate Therapeutics (Ticker: FATE), holds ― shares in Editas Medicine (Ticker: EDIT), holds 615.38K shares in aTyr Pharma (Ticker: LIFE). Most recently, John Mendlein Bought ― shares of Fate Therapeutics on Jan 20, 2023 for an estimated value of 38.99K.